author-photo

Bruce J. Dezube

Beth Israel Deaconess Medical Center
Harvard University

223

Papers

12581

Citations

Citation Trend

Filter By

Papers (178) Sort By

Journal Conference Others

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.

2020 Nature Communications
Show All
- Source
- Cite
- Save
Citations (73)
Abstract 4487: Association of the tumor-immune microenvironment with response to niraparib and pembrolizumab in relapsed, platinum-resistant ovarian cancer

2019 Immunology
Show All
- Source
- Cite
- Save
Citations (0)
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

2019 JAMA Oncology
Show All
- Source
- Cite
- Save
Citations (154)
Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

2019 JAMA Oncology
Show All
- Source
- Cite
- Save
Citations (105)
Abstract OT3-03-01: Open-label, single-arm study evaluating the antitumor activity and safety of niraparib as neoadjuvant treatment in patients with localized,HER2-negative,BRCA-mutant breast cancer

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (74)
Topacio: Preliminary activity and safety in patients (pts) with platinum-resistant ovarian cancer (PROC) in a phase 1/2 study of niraparib in combination with pembrolizumab

2018 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (14)
1143PDDose-finding combination study of niraparib and pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or recurrent platinum-resistant epithelial ovarian cancer (OC) (TOPACIO/Keynote-162)

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (10)
Treatment patterns among patients with higher-risk myelodysplastic syndromes in a real-world setting: Electronic medical record (EMR)-based data.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008)

2015 Cancer Immunology, Immunotherapy
Show All
- Source
- Cite
- Save
Citations (75)